CRVSClinical•globenewswire•
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
Sentiment:Positive (65)
Summary
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by globenewswire